Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Memphasys Ltd ( (AU:MEM) ) has shared an announcement.
Memphasys Limited has announced a change in its company secretary, with Mr. Andrew Metcalfe concluding his role and Mr. Stefan Ross stepping in as the new Company Secretary effective 8 October 2025. Mr. Ross brings over 17 years of experience in governance and compliance, which will be instrumental as Memphasys progresses the commercialisation of its Felix™ System, aiming to establish it as a global standard in sperm selection.
More about Memphasys Ltd
Memphasys Limited (ASX: MEM) is focused on the commercialisation of its patented Felix™ System, a novel bioseparation technology for assisted reproduction. Felix™ combines electrophoresis with proprietary size-exclusion membranes to rapidly isolate the most viable sperm cells for use in human fertility treatments. The company’s strategy is centred on securing contracted sales, driving adoption through key clinical and distribution partnerships, and scaling production capacity. With regulatory and commercial pathways advancing, Memphasys is positioned to deliver on its vision of establishing Felix™ as a new global standard in sperm selection.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.46M
See more insights into MEM stock on TipRanks’ Stock Analysis page.